New hope for kids with seizures: cenobamate trial launches
NCT ID NCT07594158
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a drug called cenobamate in 20 Japanese children aged 2 to 17 who have partial-onset seizures that are not fully controlled by current treatments. The main goal is to see if the drug is safe and tolerable. Participants will take cenobamate tablets daily, with doses adjusted based on their response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cenobamate (tablet)
- What this could lead to
- If successful, cenobamate could offer a new treatment option to help control partial seizures in children with epilepsy.
- What could go wrong
- This is a small, open-label study with only 20 participants, so results may not apply broadly. Side effects are possible, and the drug may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARTIAL EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Japan Red Cross Fukuoka Hospital
RECRUITINGFukuoka, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study sheds light on brain signals during seizures in children
- Scientists zap brains to map thinking in epilepsy
- New epilepsy drug tested in kids for first time
- New study screens epilepsy patients for future breakthroughs
- New hope for kids with focal seizures: cenobamate trial underway
- Surgery offers hope for Drug-Resistant epilepsy patients